PRODUCTION AND TESTING OF A MODIFIED VACCINIA ANKARA (MVA) VACCINE
$1,421,912N01FY2015AINIH
Sanofi Pasteur Biologics, Llc, Cambridge MA
Investigators
Abstract
The purpose of this contract is to support the advanced development and manufacture of a Modified Vaccinia Ankara (MVA) smallpox vaccine.
View original record on NIH RePORTER →